Cynosure's Smartlipo Triplex(TM) Technology Shows Superior Skin Tightening and Fat Disruption in Laser-Assisted Lipolysis

WESTFORD, Mass., April 15 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO) today announced the presentation of a new study that demonstrates the clinical benefits of using a 1440 nm wavelength in laser-assisted lipolysis to disrupt fat tissue and tighten skin through tissue coagulation.  The study, led by Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery, is one of six Cynosure-related abstracts being presented this week at the 2010 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Arizona.

Dr. DiBernardo's study evaluated the fat-disruption and tissue tightening that occurred in abdominal tissue treated with three separate wavelengths, including a 1440 nm laser.  The 1440 nm wavelength is the heart of Cynosure's Smartlipo Triplex, which was introduced in late 2009 as the newest member of Cynosure's family of workstations for laser-assisted lipolysis.  The Smartlipo Triplex is the highest-power laser energy device approved for fat removal by the U.S. Food and Drug Administration.

"At the same power and doses, tissue treated with the 1440 nm laser disrupted a larger area of fat tissue and demonstrated greater tissue tightening effects than the other wavelengths," Dr. DiBernardo said. "The conclusion that can be drawn from this research is that, in terms of the efficiency of fat removal and collagen remodeling, wavelength and laser energy play an integral role in patient outcomes.  In comparing these three unique wavelengths, the results from the 1440 nm laser demonstrated the most pronounced histological effects."

Michael Davin, president and chief executive officer of Cynosure, said, "The research presented at ASLMS further validates the investment we have made to increase the efficiency and performance of our Smartlipo technology with the addition of a 1440 nm wavelength.  The higher-powered laser, combined with enhancements such as SmartSense with ThermaGuide, which monitors and controls the flow of energy during laser-assisted lipolysis, gives our technology a strong competitive advantage in the marketplace.  Moreover, the study highlights a tenet of our corporate strategy – to support our brands with comprehensive scientific research."

Highlights from other Smartlipo-related abstracts being presented at ASLMS this week, include:

• A 15-patient study conducted by John Millard, M.D. of the Millard Plastic Surgery Center in Colorado, who describes the successful use of the Smartlipo Triplex to not only improve body contour but also to highlight the three-dimensional muscular definition of areas including the arms, legs and abdomen.  "All outcomes were considered good or excellent, with adequate improvement in muscle definition," Dr. Millard reported.
• Plastic surgeons Robert Gotkin, M.D. and Alberto Goldman, M.D., used the dual-wavelength Smartlipo MPX in a 20-patient study of women who underwent laser lipoabdominoplasty, a procedure to reduce the elevation of the abdominal flap.  All patients tolerated the surgery well, without major complications.  In comparison with the traditional and more invasive abdominoplasty procedure, the researchers concluded that the Multiplex procedure increased the contraction of skin and fat tissue, reduced the operative trauma associated with the procedure  and enhanced the patients' post-operative recovery experience.

"We are delighted with the results of these clinical studies, which highlight both the safety and efficacy of our device within potential expanded applications for our Smartlipo technology," Davin said.

In addition to the research on laser-assisted lipolysis, Cynosure's technology is featured in the following presentations at the ASLMS Annual Conference:

• "A Prospective Study of the Improvement in Peri-Orbital Wrinkles and Eyebrow Elevation with a Novel Fractional CO2 Laser," Bruce E. Katz, M.D., Clinical Professor, Mt. Sinai School of Medicine, Director, JUVA Skin & Laser Center, Director, Cosmetic Surgery & Laser Clinic, Mt. Sinai Medical Center, New York, New York; Dvora Ancona, University of Pavia, Milan, Italy
• Combined Therapy for Neck Rejuvenation: Fractional Non-Ablative Laser and Stabilized Hyaluronic Acid Based Gel of Non-Animal Origin: A Clinicopathologic Study with Special Attention Given to the Histology," Adriana Ribe, Natalia Ribe, Institut Dra Natalia Ribe, Barcelona, Spain
• "Treatment of Carbon Tattoos in a Porcine Model with a Novel 758 nm, 500 Picosecond  Laser," Leonid Izikson, William Farinelli, Zeina Tannous, Fedrnanda Sakamoto, R. Rox Anderson, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts

About ASLMS

The American Society for Laser Medicine and Surgery is the world's largest scientific organization dedicated to promoting research, education and high standards of clinical care in the field of medical laser applications. It provides a forum for the exchange of scientific information and participates in communicating the latest developments in laser medicine and surgery to clinicians, research investigators, government and regulatory agencies, and the public.  Founded in 1980, the Society has more than 4,000 members.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite.  Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.  For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economic recession and its effects on the aesthetic laser industry, Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission.  In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release.  Cynosure anticipates that subsequent events and developments will cause its views to change.  However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

SOURCE Cynosure, Inc.